Breast Cancer Rapid Recommendation Update on Capivasertib-Fulvestrant
Posted March 26, 2024
On February 6, a rapid recommendation update on Capivasertib-Fulvestrant was published. The rapid update has implications for two guidelines: Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancers and Biomarkers for Systemic Therapy in Metastatic Breast Cancer.